The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study

키워드

참고문헌 (34)

1. Dray A, "Inflammatory mediators of pain", Br J Anaesth, 75, pp.125~131 (1995)
2. Yoshida N, "Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease", Scand J Gastroenterol, 39, pp.816~822 (2004)
3. Labenz J, "A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study", Aliment Pharmacol Ther, 21, pp.739~746 (2005)
4. Bochenek WJ, "Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis", Aliment Pharmacol Ther, 20, pp.1105~1114 (2004)
5. Arakawa T, "15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications", Dig Dis Sci, 50(1), pp.S3~S11 (2005)
6. Laheij RJ, "Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett’s oesophagus", Aliment Pharmacol Ther, 16, pp.887~891 (2002)
7. Chitapanarux T, "An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors", Dig Dis Sci, 53, pp.2896~2903 (2008)
8. Yoshida N, "Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole", Dig Dis Sci, 55, pp.3393~3398 (2010)
9. Lundell LR, "Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification", Gut, 45, pp.172~180 (1999)
10. Tytgat GN, "The Sydney System: endoscopic division. Endoscopic appearances in gastritis", duodenitis, 1991, pp.6, 223~234
11. Fass R, "The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis", Aliment Pharmacol Ther, 14, pp.389~396 (2000)
12. Gillen P, "Implication of duodenogastric reflux in the pathogenesis of Barrett’s oesophagus", Br J Surg, 75, pp.540~543 (1988)
13. Nehra D, "Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity", Gut, 44, pp.598~602 (1999)
14. Tobey NA, "The role of pepsin in acid injury to esophageal epithelium", Am J Gastroenterol, 96, pp.3062~3070 (2001)
15. Thangarajah H, "Gastric H-K-ATPase and acid-resistant surface proteins", Am J Physiol Gastrointest Liver Physiol, 282, pp.G953~G961 (2002)
16. Orlando RC, "Pathophysiology of gastroesophageal reflux disease", J Clin Gastroenterol, 42, pp.584~588 (2008)
17. Fitzgerald RC, "Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants", Gut, 50, pp.451~459 (2002)
18. Isomoto H, "Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis", Am J Gastroenterol, 98, pp.551~556 (2003)
19. Yamaguchi T, "Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux esophagitis in rats", Int J Mol Med, 16, pp.71~77 (2005)
20. Wetscher GJ, "Reflux esophagitis in humans is mediated by oxygen-derived free radicals", Am J Surg, 170, pp.552~556 (1995)
21. Wetscher GJ, "Esophagitis in Sprague-Dawley rats is mediated by free radicals", Dig Dis Sci, 40, pp.1297~1305 (1995)
22. Dvorak K, "Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage:relevance to the pathogenesis of Barrett’s oesophagus", Gut, 56, pp.763~771 (2007)
23. Dvorak K, "Esophageal acid exposure at pH <or = 2 is more common in Barrett’s esophagus patients and is associated with oxidative stress", Dis Esophagus, 19, pp.366~372 (2006)
24. Fellenius E, "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ +K+)ATPase", Nature, 290, pp.159~161 (1981)
25. Yokota T, "Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells", Eur J Pharmacol, 481, pp.233~240 (2003)
26. Haga Y, "Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor", Dig Dis Sci, 43, pp.253~257 (1998)
27. Lo WK, "Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis", Clin Gastroenterol Hepatol, 11, pp.483~490 (2013)
28. Sheen E, "Adverse effects of long-term proton pump inhibitor therapy", Dig Dis Sci, 56, pp.931~950 (2011)
29. Higuchi K, "Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils", Aliment Pharmacol Ther, 18(1), pp.1~7 (2003)
30. Katada K, "Prevention by rebamipide of acute reflux esophagitis in rats", Dig Dis Sci, 50(1), pp.S97~S103 (2005)
31. Hagiwara T, "Rebamipide contributes to reducing adverse effects of long-term administration of omeprazole in rats", Dig Dis Sci, 52, pp.988~994 (2007)
32. Adachi K, "A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory nonerosive reflux disease", Dig Dis Sci, 57, pp.1609~1617 (2012)
33. Cunha FQ, "Interleukin-8 as a mediator of sympathetic pain", Br J Pharmacol, 104, pp.765~767 (1991)
34. Summer GJ, "Proinflammatory cytokines mediating burn-injury pain", Pain, 135, pp.98~107 (2008)

관련 논문AI추천